Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 23, 2017
Pharmacy Choice - News - Pharmaceutical Development - February 23, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/23/17 - Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is attending the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation and the Center for International Blood
2/23/17 - Aphios Pharma to Develop FDA-Approved, Cannabis-Based Drugs for Opioid Addiction, Epilepsy and Multiple Sclerosis [Sudan Tribune]
-Aphios Corporation today announced that it is spinning-off Aphios Pharma to develop FDA- approved, cannabis-based drugs for treating highly unmet Central Nervous System disorders such as opioid addiction, epilepsy including childhood epilepsy and multiple sclerosis that are only partially and anecdotally addressed by medical marijuana.
2/23/17 - Auris Medical and King`s College London Extend Tinnitus Collaboration [Press TV (Iran)]
-Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the extension of its collaboration with King`s College London. Professor David E. Thurston of the Institute of Pharmaceutical Science is leading the team at King`s to develop and opti
2/23/17 - BeyondSpring Clinical Data for Lead Asset, Plinabulin, Accepted for Oral Presentation at IASLC's 2017 Targeted Therapies of the Treatment of Lung Cancer
BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company's clinically and statistically significant data for its innovative lead asset, Plinabulin, has been accepted for oral presentation at this year's International...
2/23/17 - BioCorRx Provides Preclinical Study Update on BICX101 Development
Webcast Available at http://www.BioCorRx.comAnaheim, CA 02/23/2017 BioCorRx Inc., a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today provided an update on the preclinical development of BICX101, a new sustained release injectable naltrexone product for the treatment of substance abuse addic
2/23/17 - Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck's KEYTRUDA (pembrolizumab)
Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA , in patients with either advanced melanoma who have progressed on treatment with a checkpoint inhibitor therapy, or with TNBC whose disease has
2/23/17 - Blog Coverage Ocular Therapeutix Announced FDA Acceptance of NDA Resubmission for its Product for the Treatment of Ocular Pain
LONDON, UK/ ACCESSWIRE/ February 23, 2017/ Active Wall St. blog coverage looks at the headline from Ocular Therapeutix, Inc. as the Company announced on February 22, 2017, that the Company's New Drug Application resubmission for DEXTENZA?, for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review
2/23/17 - Cadila Healthcare receives approval from USFDA [India Infoline News Service]
Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from Primary Biliary. Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from...
2/23/17 - CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Programmed Death-1 antibody, CBT-501, at ASCO-SITC Clinical Oncology Symposium
The data were presented in a poster at the American Society of Clinical Oncology Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium being held from February 23 25, 2017 in Orlando, Florida. The strong in-vivo preclinical data suggest that CBT-501 may have clinical benefit in a variety of tumor types, said Sanjeev Red
2/23/17 - Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis [All Iraq News Agency (AIN)]
-Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced progression of its ongoing Phase 2 clinical trial of Brilacidin to the third cohort for induction of remission of mild-to-moderate ulcerative colitis after..
2/23/17 - China Exclusive: Chinese affordable lung cancer drug hits market [Philippines News Agency]
Its release ends an almost decade-long monopoly by Iressa, developed by British multinational biopharmaceutical company AstraZeneca and introduced to China in 2005.. Yiruike was approved for marketing by China's State Food and Drug Administration after Iressa's patent protection expired in April 2016, Qilu sources said. The drug is a much-needed fi
2/23/17 - Chrysalis BioTherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
By a News Reporter-Staff News Editor at Politics& Government Week- Chrysalis BioTherapeutics, Inc. announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear..
2/23/17 - Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael Knowles, M.D., a member of the Company's Scientific Advisory Board and Professor of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill will pre
2/23/17 - Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism The Blm Study
Curemark, LLC announced today that the Blm Study, a Phase 3 clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. Joan Fallon, founder and CEO of Curemark. "Making our clinical trial available to as many children across the United States as possible, is an important ste
2/23/17 - Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported top-line results from the pivotal Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid le
2/23/17 - Diagnostic Imaging Market Worth 36.43 Billion by 2021
According to a new market research report " Diagnostic Imaging Market by Product, MRI, Ultrasound, CT, Nuclear Imaging), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers)- Global Forecast to 2021", published by MarketsandMarkets, the report studies the global market over the forecast period of 2016 to 2021. The
2/23/17 - FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
By a News Reporter-Staff News Editor at Gene Therapy Weekly- Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc., reported that the FDA has granted Fast Track designation for the Phase 3 clinical investigation of Generx cardiovascular angiogenic gene therapy as a one-time treatment for improving exercise...
2/23/17 - Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the first patient has been dosed in the Phase I portion of the Phase I/II clinical trial of FCX-007, the Company s gene therapy candidate for the treatment of Recessive Dystro
2/23/17 - Finch Therapeutics Announces Strategic Collaboration with OpenBiome to Develop Microbiome Therapies for FDA Approval
Finch Therapeutics, Inc., a microbiome therapeutics company, and OpenBiome, a leading public stool bank, today announced a collaboration to develop FIN-403, an orally administered microbial therapy for approval by U.S. Food and Drug Administration in recurrent C. difficile infections. OpenBiome has transformed the standard of care for C. diffici
2/23/17 - Flex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Regulation FD Disclosure
Flex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Regulation FD Disclosure Item 7.01 Regulation FD Disclosure. On February 23, 2017, Flex Pharma, Inc. (the Company) will present a poster entitled Flex-201: A Multicenter, Randomized, Blinded Study to Evaluate the Efficacy and Tolerability of FLX-787 in MS at the Americas Committee for Treatme
2/23/17 - Flexion Therapeutics Initiates Clinical Trial to Evaluate the Safety of Repeat Administration of Zilretta? (FX006) in Patients with Osteoarthritis of the Knee
Flexion Therapeutics, Inc. today reported it has enrolled the first patient in a clinical trial to evaluate the safety of repeat administration of its investigational drug candidate Zilretta in patients with osteoarthritis of the knee. The open-label study is expected to enroll approximately 200 patients at up to 20 clinical sites in the United S
2/23/17 - GNW-News: Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC (english)
Novartis International AG/ Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC. *FDA also grants Breakthrough Therapy designation based on Phase III data in. brain* If approved in the first-line setting, Zykadia will offer previously untreated ALK+ metastatic NSCLC patients a new treatment op
2/23/17 - H3 Biomedicine Announces Appointment of Peter G. Smith, Ph. D., to Chief Scientific Officer [Palestine News Network]
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisais global Oncology Business Group, announced today that Peter G. Smith, Ph.D., will become the companys chief scientific officer, effective March 1, 2017. In his role as chief scientific officer, Dr.
2/23/17 - IDC Receives FDA Approval for Innovative DR Imaging Devices
Calgary, Alberta- Imaging Dynamics Company Ltd. is pleased to announce that it received notification today that the United States Food and Drug Administration has granted Market Clearance approval for its new Digital Radiography product line- Aquarius 8600 1717 TC and Aquarius 8600 1417 TC. These products utilize and integrate into IDC s proprie
2/23/17 - IFM Therapeutics Appoints Renowned Physicians from Academia and Industry to Clinical Advisory Board
IFM Therapeutics, a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system for the treatment of cancer and inflammatory disease, today announced the appointment of seven leading physicians to its clinical advisory board. We are delighted to welcome this accomplished and distinguished
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement